https://www.avient.com/sites/default/files/2024-05/AVNT Q1 2024 Earnings Presentation_For_Website_w_non-GAAP_5_6_1.pdf
In particular, these include statements relating to future actions; prospective changes in raw material costs, product pricing or product demand; future performance; estimated capital expenditures; results of current and anticipated market conditions and market strategies; sales efforts; expenses; the outcome of contingencies such as legal proceedings and environmental liabilities; and financial results.
Factors that could cause actual results to differ materially from those implied by these forward-looking statements include, but are not limited to: • Disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; • The effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; • Disruptions or inefficiencies in our supply chain, logistics, or operations; • Changes in laws and regulations in jurisdictions where we conduct business, including with respect to plastics and climate change; • Fluctuations in raw material prices, quality and supply, and in energy prices and supply; • Demand for our products and services; • Production outages or material costs associated with scheduled or unscheduled maintenance programs; • Unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; • Our ability to pay regular quarterly cash dividends and the amounts and timing of any future dividends; • Information systems failures and cyberattacks; • Amounts for cash and non-cash charges related to restructuring plans that may differ from original estimates, including because of timing changes associated with the underlying actions; • Our ability to achieve strategic objectives and successfully integrate acquisitions, including the implementation of a cloud-based enterprise resource planning system, S/4HANA;and • Other factors affecting our business beyond our control, including without limitation, changes in the general economy, changes in interest rates, changes in the rate of inflation, geopolitical conflicts and any recessionary conditions Use of Non-GAAP Measures This presentation includes the use of both GAAP (generally accepted accounting principles) and non-GAAP financial measures.
https://www.avient.com/sites/default/files/2020-08/fiber-solutions-business-unit-overview-2020.pdf
LIQUID FIBER PRODUCT FEATURES Multiple color production • Depending on the manufacturing set-up, several injection points can be added to enable multiple color production at the same time on a single extruder Batch size flexibility • Fiber producers can manufacture anything from a few kilograms to hundreds of tons using the same simple process Rapid color changes • No extruder contamination and easy color-on, color-off operation increases color change speed Waste reduction • Rapid color changes, precise metering and the ability to adjust color in-line reduces waste during color changeovers Continuous metering & long spin pack life • High pigment and dye concentrations mean fewer pack changes are required • Where color is running low for larger volume runs, low level metering sensors alert operators and packs can be changed without disrupting production In-line IV adjustment • Specialist additives are available to adjust Intrinsic Viscosity (IV) in-line for rPET applications • These additives are available as single products, or can be combined with color to create a multi-functional formulation Color design service • ColorMatrix offers a dedicated color design service to help shorten product development cycles and enhance market agility Liquid color processing • Formulations are stable at temperatures up to 60°C and retain good flow properties at temperatures as low as 10°C • These formulations can help lower yarn friction and abrasion, and there is no fuming or evaporation during production COLORMATRIX FLEXCART LIQUID DOSING SYSTEMS Designed to optimize the benefits of liquid colorant and additive technologies, each ColorMatrix™ FlexCart™ model is highly flexible, and offers high-level dosing accuracy and controllability for all injection molding and extrusion applications.
https://www.avient.com/sites/default/files/2022-08/Environmental Stress Cracking Resistance _ESCR_ Design Guide %281%29.pdf
Increased stresses during processing localize in areas of changing geometry due to non-uniform flow and differential cooling rates.
Figure 3 also shows how the wall thickness can suddenly change when outside and inside rounds are not concentric.
The design of a rib should be derived from the structural, flow, and assembly requirements of the part.2 FIGURE 5 - Proper contour design FIGURE 6 - Drafting guidelines for nominal wall thickness FIGURE 7 - Wall thickness changes due to rib placement FIGURE 8 - Rib design guidelines ESCR Design Guide 3 BOSSES A boss, demonstrated in Figure 9, is a protruding feature that allows for fastening components.
https://www.avient.com/sites/default/files/2023-11/AVNT Q3 2023 Earnings Presentation - Website.pdf
In particular, these include statements relating to future actions; prospective changes in raw material costs, product pricing or product demand; future performance; estimated capital expenditures; results of current and anticipated market conditions and market strategies; sales efforts; expenses; the outcome of contingencies such as legal proceedings and environmental liabilities; and financial results.
Factors that could cause actual results to differ materially from those implied by these forward-looking statements include, but are not limited to: • Disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; • The effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; • Changes in laws and regulations regarding plastics in jurisdictions where we conduct business; • Fluctuations in raw material prices, quality and supply, and in energy prices and supply; • Production outages or material costs associated with scheduled or unscheduled maintenance programs; • Unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; • Our ability to achieve strategic objectives and successfully integrate acquisitions, including Avient Protective Materials (APM); • An inability to raise or sustain prices for products or services; • Our ability to pay regular quarterly cash dividends and the amounts and timing of any future dividends; • Information systems failures and cyberattacks; • Amounts for cash and non-cash charges related to restructuring plans that may differ from original estimates, including because of timing changes associated with the underlying actions; and • Other factors affecting our business beyond our control, including without limitation, changes in the general economy, changes in interest rates, changes in the rate of inflation, any recessionary conditions, and terrorism or hostilities Use of Non-GAAP Measures This presentation includes the use of both GAAP (generally accepted accounting principles) and non-GAAP financial measures.
https://www.avient.com/sites/default/files/2023-01/Mevopur Healthcare Functional Additives_Laser Welding Additives for Medical Devices Application Bulletin.pdf
KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number, reducing risk of change • Available as additive concentrates, ready-to-use additive formulations or ready-to-use additive/ colorant formulations for different polymers REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* APPLICATION BULLETIN * FDA/EU compliance information available upon request; exceptions may occur Healthcare use limitations apply—see below.
https://www.avient.com/sites/default/files/2023-03/Cesa Nox A4R Product Bulletin_0.pdf
PRODUCT BULLETIN Cesa™ Nox A4R Additives for Recycling Polyolefin Antioxidant for Enhanced Recycling RECYCLED MATERIAL IN A CHANGING MARKET Legislation globally is driving change towards increased quantities of post-consumer recycled materials (PCR), further encouraged by the implementation of usage targets and new tariffs.
https://www.avient.com/sites/default/files/2022-10/Hoyt VITALPOINT Grip Case Study.pdf
HITTING THE SWEET SPOT FOR ARCHERY ENTHUSIASTS SPECIALTY MATERIALS AND UPGRADED DESIGN ACHIEVE GAME-CHANGING PRECISION © 2022, All Rights Reserved Avient Corporation, 33587 Walker Road, Avon Lake, Ohio USA 44012 Interested in learning more about specialty TPEs or advancing your design?
This change reduced fatigue, which then resulted in less movement and a more precise shot.
https://www.avient.com/sites/default/files/2022-12/Mevopur Healthcare Bio-based Polymer Solutions Application Bulletin.pdf
KEY CHARACTERISTICS • Available for polyethylene, polypropylene, ABS, polycarbonate and styrenics • Bio-content of resin carrier varies from 70% to 100% depending on polymer—calculated to ASTM D6866 standard • Manufactured at four ISO 13485 certified sites, providing global consistency and security of supply • Documented change control beyond CAS number, reducing risk of change • Drop-in solutions that can be processed like fossil-based grades on common injection molding and extrusion machines • Can be provided as ready-to-use pre-colored or additive formulation REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 - USP and (incl. class VI) - European Pharmacopeia, monograph 3.1.3/ 3.1.5 (polyolefin packaging materials) - USP (polyethylene) - Elemental impurities as per ICH Q3D • Registered Drug Master File (Type III) and/or Device Master File • Food contact according to US FDA and APPLICATION BULLETIN Sustainability Spotlight Bio-polymers Healthcare use limitations apply—see below.
https://www.avient.com/sites/default/files/2023-03/Mevopur Healthcare Functional Additives Nucleating Application Bulletin.pdf
REGULATORY SUPPORT • Drug delivery devices • Pharmaceutical packaging • Medical equipment KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number level, reducing the risk of change • Allows crystallization in semi-crystalline polymers to begin faster and complete earlier REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* APPLICATION BULLETIN * FDA/EU compliance information available upon request Healthcare use limitations apply—see below.
https://www.avient.com/sites/default/files/2023-05/Mevopur Healthcare Colorants and Formulations Amber for Pharma Application Bulletin.pdf
KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number level, reducing risk of change • Non-phthalate and formulated without animal-derived substances • Different tones of amber available on request —more or less red or yellow and/or lighter or darker • Also available in liquid form REGULATORY SUPPORT • Pre-tested raw materials: - ISO 10993-1 and USP parts (Class VI) - European Pharmacopeia, monograph 3.1.15, USP and elemental analysis as per ICH Q3D - USP criteria appearance of solution, color • Registered Drug Master File (Type III) by the FDA • Food contact compliance established with FDA/EU* • YBB00102002-2015 (oral liquid pharmaceutical PET bottles) compliance support APPLICATION BULLETIN * FDA/EU compliance information available upon request Healthcare use limitations apply—see below.